University of Torino
Colorectal Cancers Dial up Mutability in Response to Targeted Treatments
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
SkylineDx Follows Multiple Myeloma MDx With Collaborative Effort to Develop Therapy Selection Assay
Premium
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
Trovagene Forms European Institute Headed by U Torino Researcher Alberto Bardelli
The new subsidiary will focus on expanding the company's liquid biopsy technology capabilities and growing European adoption of its platform.
Adaptive Bio, MMRF, U of Torino Collaborate on Sequencing-based MRD Monitoring in Myeloma Patients
The partners will compare Adaptive Bio's clonoSeq MRD test with flow cytometry for accuracy and reliability in monitoring MRD in multiple myeloma patients.
As research reveals tumor features that can affect circulating tumor DNA levels, investigators are considering several sequencing and PCR-based clinical applications for the bloodstream-borne nucleic acids — from early detection and diagnosis to minimal residual disease monitorin